A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

News

News

All the latest news about the Access to Medicine Foundation, our research programmes and engagement activities. 

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

23 Feb 2021

Investors issue urgent call for “fair and equitable” global response to COVID-19

Today, almost 150 institutional investors have issued a joint call for a fair and equitable global response to the pandemic, including through fully f...

25 Jan 2021

Now online: 2021 Access to Medicine Index

Pharma companies move to systematically make new medicines rapidly accessible to the poor. The 2021 Access to Medicine Index identifies eight pha...

24 Nov 2020

The materiality of superbugs: risks and opportunities for pharma investors from antimicrobial resistance

Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimic...

23 Nov 2020

First investor partners named in joint initiative against 'super-sized' AMR threat

As World Antimicrobial Awareness Week begins, 12 global investors and financial institutions have announced they are joining the Investor Action on AM...

20 Nov 2020

Sharing surveillance data: the value of collaboration in curbing the next pandemic

Monitoring the spread of infectious diseases through surveillance programmes is fundamental to maintaining good public health and a key component of s...

20 Oct 2020

Bridging the gap in access to oxygen: Foundation coordinates on key actions for industry

Oxygen is critical in the treatment of pneumonia, which claims the lives of more than 672,000 children under 5 every year. Further, one in five COVID-...

06 Oct 2020

2021 Benchmark framework to track pharma's progress against superbugs

The rise of treatment-resistant bacterial and fungal diseases poses a direct threat both to modern medicine and our way of living. The Antimicrobial R...

02 Oct 2020

Which information matters most? Transparency by Pharma that builds access to medicine plus trust and engagement

The world depends on the pharmaceutical industry for life-saving medicines and vaccines yet trust in the industry is low. Pharmaceutical companies hav...

16 Jul 2020

Tunnel vision or global outlook? Global pharma's dependency on the US

COVID-19 is a litmus test of whether health systems can pool assets and expertise and fairly distribute resources so that patients worldwide can benef...

09 Jun 2020

Progress against HIV, malaria and TB is under threat, putting children at risk. Here’s what is needed.

COVID-19 and drug resistance are threatening to derail the progress made against the HIV, malaria and TB epidemics. With the last mile in sight, great...

15 Apr 2020

Pharma’s path to 2030 captured in new framework for next Access to Medicine Index

The UN has called for a decade of action to achieve the Sustainable Development Goals and universal health coverage by 2030. Action by pharmaceutical...

14 Apr 2020

New products alone are not enough. Pharma can do more to halt COVID-19.

The COVID-19 epidemic will hit the most vulnerable people hardest. The pharmaceutical industry has a responsibility to do more than develop new vaccin...

20 Feb 2020

100+ investors endorse the Access to Medicine Index

Eight new investors have pledged support to the Foundation’s research and signed the Access to Medicine Index Investor Statement, taking the tota...

21 Jan 2020

Signs of progress against the superbugs, but not yet at the scale needed

The 2020 Antimicrobial Resistance Benchmark evaluates how 30 pharmaceutical companies are limiting drug-resistance. Amsterdam, the Netherlands, 21 Ja...

19 Nov 2019

Out in Jan: 2nd Benchmark of pharma companies' actions on antibiotic resistance and access

The 2020 Antimicrobial Resistance Benchmark will be published in January next year. In this new report, the Access to Medicine Foundation will address...

29 Aug 2019

Foundation names Expert Review Committee for next Access to Medicine Index

The Foundation is pleased to announce the members of the Expert Review Committee for the next Access to Medicine Index, including six new members in 2...

Back to top |